Rezolute

Diabetic macular oedema
#Biopharmaceuticals #Diabetes #Ophthalmology #Phase II trial #Rezolute

Oral therapy for diabetic macular oedema progresses to Phase II

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO).   The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye,… Read More

#News